Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2024-10-03 Regulatory Filings
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing Kane Biotech's participation in a multinational corporate collaboration project, including funding details and project goals. It contains no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. It is not an earnings release, annual or interim report, or any form of audit or management report. The content is primarily an update on a corporate collaboration and funding received, which fits best under a general regulatory announcement category. The document length is 4328 characters, which is relatively short and does not contain detailed financial data or report content. Therefore, it is classified as a Regulatory Filing (RNS).
2024-10-03 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the exercise of warrants by Kane Biotech, including details about the number of warrants exercised, exercise price, and proceeds raised. It focuses on a financing activity (warrant exercise) and the use of proceeds for working capital. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is short (3143 characters) and is an announcement of a capital raising event rather than a full financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-09-12 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing the upcoming release date of Kane Biotech's second quarter 2024 financial results and the scheduling of a conference call to discuss those results. It does not contain the actual financial results or detailed financial data. The document length is 3455 characters, which is relatively short and consistent with an announcement rather than a full report. The text explicitly states the results will be announced on August 29, 2024, and that a conference call will follow. This fits the pattern of an Earnings Release announcement or a notice about the earnings release and conference call. However, since it does not contain the financial results themselves but only the announcement of the release and call, it is best classified as an Earnings Release (ER) type, which includes initial announcements of quarterly financial results and key highlights. The document is not a full transcript, management discussion, or regulatory filing, nor is it a report publication announcement because it does not mention the report being attached or available. Therefore, the best classification is Earnings Release (ER).
2024-08-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new distribution agreement for a product (revyve™ Antimicrobial Wound Gel) in the Middle East. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or governance information. It is a corporate announcement about a commercial partnership, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is best classified as a general corporate announcement about a business development, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2024-08-22 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Kane Biotech is receiving funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to expand its product line. It details the nature of the funding, the intended use for product development, and includes forward-looking statements about the company's strategy and risks. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an update on capital/funding activities rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-08-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Kane Biotech has received FDA approval to increase the dosage allowance of its revyve™ Antimicrobial Wound Gel. It discusses regulatory approval and product development but does not contain financial statements, detailed financial performance, or management discussion of financial results. The document length is 3719 characters, which is relatively short and typical for a press release. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the announcement itself. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best with a general regulatory announcement or company update rather than a specific financial or governance filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and press releases that do not fit other categories.
2024-07-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.